ClinicalTrials.gg
CompletedNCT00833638Updated Aug 24, 2010Results posted

A Study in Erectile Dysfunction

A Phase 4 interventional study of Placebo and Tadalafil in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-08-24.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
372
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
17th of 56
372 · median 199
Started
2009
with 4 others
Phase 4
26 of 57
3 open now
Registered
22nd of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 17th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2009, is one of 26 in phase 4, and was the 22nd registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The purpose of this study is to determine the day of onset of efficacy of tadalafil dosed once-a-day.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Erectile Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and at least 18 years old, with at least a 3-month history of erectile dysfunction (ED).
  • Anticipate having same adult female sexual partner during the study.
  • Agree to make at least 4 sexual intercourse attempts with the female partner during the 4-week run-in phase without medication.
  • Agree to make at least 1 sexual intercourse attempt per day with the female partner during days 1-4 following randomization (with a minimum of three attempts required during that period). Also agree to make at least 3 intercourse attempts during days 5-14 following randomization.
  • Agree not to use any other ED treatment during the study and for 24 hours after the final study visit.

Partner Inclusion Criteria:

  • Female and at least 18 years old.
  • Agree to make at least 4 sexual intercourse attempts with the male sexual study partner during the 4-week run-in phase without medication.
  • Agree to make at least 1 sexual intercourse attempt per day with the male partner during days 1-4 following randomization
  • Agree to make at least 3 intercourse attempts during days 5-14 following randomization.

Exclusion criteria

Exclusion Criteria:

  • Previous or current treatment with tadalafil or any phosphodiesterase type 5 (PDE5) inhibitor on a daily basis for once daily use.
  • ED caused by other primary sexual disorders, or untreated or inadequately treated endocrine disease.
  • History of radical prostatectomy, other pelvic surgery or penile implant.
  • penile deformity in the opinion of the investigator.
  • Clinically significant renal insufficiency, or hepatobiliary disease as determined by the investigator.
  • Glycosylated of >11%.
  • Present with chronic stable angina treated with long-acting nitrates, or with chronic stable angina requiring short-acting nitrates in the last 90 days, or with angina occurring during sexual intercourse in the last 6 months.
  • Have any significant cardiac conditions as described in the protocol exclusion criteria.
  • Have a history of significant central nervous system injuries within the last 6 months.
  • Have a history of infection.
  • Have any condition that would interfere with the subject's ability to provide or comply with study instructions, would place subject at increased risk, or might confound the interpretation of the study results.
  • Currently receive treatment with nitrates, cancer chemotherapy, or antiandrogens (except finasteride taken as Propecia or Proscar, or Avodart [dutasteride]).
  • History of drug, alcohol, or substance abuse within the past 6 months, as assessed by the investigator.
  • Previously completed or withdrawn from any other study investigating tadalafil for once daily use.
  • Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
  • Prior ineffective treatment with any PDE5 inhibitor in the opinion of the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
372 participants (actual)

Study arms

  • Experimental
    Tadalafil 2.5 mg

    No drug during baseline period, 2.5 mg for 14 days, then will continue at 5 mg for 14 days.

    Drug: Tadalafil

  • Experimental
    Tadalafil 5 mg

    No drug during baseline period, 5 mg for 14 days, then will continue at 5 mg for 14 days.

    Drug: Tadalafil

  • Placebo comparator
    Placebo

    No drug during baseline period, placebo for 14 days, then will continue tadalafil at 5 mg for 14 days.

    Drug: Placebo · Drug: Tadalafil

Interventions

  • DrugPlacebo

    One tablet orally daily

  • Orally once daily

    Also known as: Cialis, LY450190

06

What researchers measure

Primary outcomes

  1. Earliest Onset Day Measured by Cumulative Percentage of Participants With Yes Response to Sexual Encounter Profile Diary Question 3

    Cumulative percentage of participants achieving successful intercourse, as measured by "yes" responses to Sexual Encounter Profile diary question 3 (SEP3). SEP3 asks if the participant's erection lasted long enough to have successful intercourse.

    Time frame: 4 days during double-blind period

Secondary outcomes

  1. Sexual Encounter Profile Diary Question Number 1, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

    Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 1: "Were you able to achieve at least some erection (some enlargement of the penis)"? Data are presented as the mean percentage of participants who answered "yes".

    Time frame: Baseline and 14 days double-blind period

  2. Sexual Encounter Profile Diary Question Number 2, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

    Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 2: "Were you able insert your penis into your partner's vagina?" Data are presented as the mean percentage of participants who answered yes.

    Time frame: Baseline and 14 days double-blind period

  3. Sexual Encounter Profile Diary Question Number 3, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

    Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 3: "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of participants who answered "yes".

    Time frame: Baseline and 14 days double-blind period

  4. Sexual Encounter Profile Diary Question Number 4, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

    Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 4: "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of participants who answered "yes".

    Time frame: Baseline and 14 days double-blind period

  5. Sexual Encounter Profile Diary Question Number 5, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

    Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 5: "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of participants who answered "yes".

    Time frame: Baseline and 14 days double-blind period

  6. Sexual Encounter Profile Diary Question 3, the Overall Distribution of Time to Onset by Yes Responses

    Assessed was the median time to onset of efficacy (day when 50% of participants have had at least 1 successful intercourse attempt) within the first 4 days of therapy based on a "yes" response to the sexual encounter profile diary question 3: "Did your erection last long enough for you to have successful intercourse?" Data are based on participants who responded "yes". For the placebo group, onset of efficacy was not reached within the first 4 days of therapy, therefore, the analysis timeframe was expanded for this group to determine the median time to onset of efficacy.

    Time frame: 4 days double-blind period

  7. Sexual Encounter Profile Diary Question 3, Daily Cumulative Percentage of Successful Intercourse Attempts

    Assessed was the cumulative precentage of successful intercourse attempts (successful attempts relative to the total number of intercourse attempts) over the 14-day double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?" Data are presented as the proportion of intercourse attempts for which participants answered "yes" relative to the total number of intercourse attempts. Total number of attempts = TNA.

    Time frame: 14 days during double-blind period

  8. Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind and Open-label Periods for Participants Who Were Assigned to Placebo in the Double-blind Treatment Period

    Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"

    Time frame: 14 days double-blind and 14 days open-label

  9. Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 2.5 mg in the Double-blind Treatment Period

    Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"

    Time frame: 14-day double-blind and 14-day open-label

  10. Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 5 mg in the Double-blind Treatment Period

    Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"

    Time frame: 14-day double-blind and 14-day open-label

  11. Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind Period and the Open-label Period for Participants Who Didn't Respond to Tadalafil 2.5 mg During Double-blind Period

    Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts in both treatment periods. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"

    Time frame: 14 days double-blind and 14 days open-label

07

Results

Posted Aug 18, 2010

Participant flow

Phase 2: Double-blind Treatment Phase
Participant flow — Phase 2: Double-blind Treatment Phase
MilestoneTadalafil 2.5 mgTadalafil 5 mgPlacebo
Started121118133
Completed111108124
Not completed10109
Withdrew: Adverse event120
Withdrew: Entry criteria not met321
Withdrew: Lost to follow-up121
Withdrew: Physician decision100
Withdrew: Protocol violation333
Withdrew: Sponsor decision002
Withdrew: Withdrawal by subject112
Phase 3: Open-label Extension Phase
Participant flow — Phase 3: Open-label Extension Phase
MilestoneTadalafil 2.5 mgTadalafil 5 mgPlacebo
Started111108124
Completed110105122
Not completed132
Withdrew: Lost to follow-up120
Withdrew: Protocol violation012

Outcome measures

PrimaryEarliest Onset Day Measured by Cumulative Percentage of Participants With Yes Response to Sexual Encounter Profile Diary Question 3

Cumulative percentage of participants achieving successful intercourse, as measured by "yes" responses to Sexual Encounter Profile diary question 3 (SEP3). SEP3 asks if the participant's erection lasted long enough to have successful intercourse.

Time frame:
4 days during double-blind period
Reported as:
Number · cumulative percentage of participants
Earliest Onset Day Measured by Cumulative Percentage of Participants With Yes Response to Sexual Encounter Profile Diary Question 3
cumulative percentage of participantsTadalafil 2.5 mgTadalafil 5 mgPlacebo
<= day 454.562.247.2
<= day 349.155.042.3
<= day 242.048.636.6
<= day 128.625.228.5
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = 0.086 (P-value for day \<=4. A fixed-sequence test was used within each dose group at each time point (days 4, 3, 2, 1) and adjusted for multiple dose-placebo comparisons using the Bonferroni method. Testing started on day 4 and stopped when p\>.025.)Model response = treatment + pooled site + severity of erectile dysfunction at baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = 0.006 (P-value for day \<=4. A fixed-sequence test was used within each dose group at each time point (days 4, 3, 2, 1) and adjusted for multiple dose-placebo comparisons using the Bonferroni method. Testing started on day 4 and stopped when p\>.025.)Model response = treatment + pooled site + severity of erectile dysfunction at baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = 0.019 (P-value for day \<=3. A fixed-sequence test was used within each dose group at each time point (days 4, 3, 2, 1) and adjusted for multiple dose-placebo comparisons using the Bonferroni method. Testing started on day 4 and stopped when p\>.025.)Model response = treatment + pooled site + severity of erectile dysfunction at baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = 0.022 (P-value for day \<=2. A fixed-sequence test was used within each dose group at each time point (days 4, 3, 2, 1) and adjusted for multiple dose-placebo comparisons using the Bonferroni method. Testing started on day 4 and stopped when p\>.025.)Model response = treatment + pooled site + severity of erectile dysfunction at baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = 0.573 (P-value for day \<=1. A fixed-sequence test was used within each dose group at each time point (days 4, 3, 2, 1) and adjusted for multiple dose-placebo comparisons using the Bonferroni method. Testing started on day 4 and stopped when p\>.025.)
SecondarySexual Encounter Profile Diary Question Number 1, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 1: "Were you able to achieve at least some erection (some enlargement of the penis)"? Data are presented as the mean percentage of participants who answered "yes".

Time frame:
Baseline and 14 days double-blind period
Reported as:
Least squares mean · percentage of participants
Sexual Encounter Profile Diary Question Number 1, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
percentage of participantsTadalafil 2.5 mgTadalafil 5 mgPlacebo
Sexual Encounter Profile Diary Question Number 1, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses1.97 ± 2.332.74 ± 2.34-10.06 ± 2.24
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 12.03 · 95% CI 5.72 to 18.34Included were terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction were included.
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 12.80 · 95% CI 6.48 to 19.12Terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction were included.
SecondarySexual Encounter Profile Diary Question Number 2, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 2: "Were you able insert your penis into your partner's vagina?" Data are presented as the mean percentage of participants who answered yes.

Time frame:
Baseline and 14 days double-blind period
Reported as:
Least squares mean · percentage of participants
Sexual Encounter Profile Diary Question Number 2, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
percentage of participantsTadalafil 2.5 mgTadalafil 5 mgPlacebo
Sexual Encounter Profile Diary Question Number 2, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses8.11 ± 2.5513.12 ± 2.56-7.29 ± 2.44
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 15.40 · 95% CI 8.51 to 22.29Included were terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction.
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 20.41 · 95% CI 13.50 to 27.31Included were terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction.
SecondarySexual Encounter Profile Diary Question Number 3, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 3: "Did your erection last long enough for you to have successful intercourse?" Data are presented as the mean percentage of participants who answered "yes".

Time frame:
Baseline and 14 days double-blind period
Reported as:
Least squares mean · percentage of participants
Sexual Encounter Profile Diary Question Number 3, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
percentage of participantsTadalafil 2.5 mgTadalafil 5 mgPlacebo
Sexual Encounter Profile Diary Question Number 3, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses15.67 ± 2.7621.94 ± 2.771.40 ± 2.64
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 14.27 · 95% CI 6.83 to 21.71Included were terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction.
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 20.54 · 95% CI 13.07 to 28.01Included were terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction.
SecondarySexual Encounter Profile Diary Question Number 4, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 4: "Were you satisfied with the hardness of your erection?" Data are presented as the mean percentage of participants who answered "yes".

Time frame:
Baseline and 14 days double-blind period
Reported as:
Least squares mean · percentage of participants
Sexual Encounter Profile Diary Question Number 4, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
percentage of participantsTadalafil 2.5 mgTadalafil 5 mgPlacebo
Sexual Encounter Profile Diary Question Number 4, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses20.94 ± 2.9028.50 ± 2.926.70 ± 2.77
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 14.24 · 95% CI 6.42 to 22.06Included were terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction.
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 21.81 · 95% CI 13.94 to 29.67Included were terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction.
SecondarySexual Encounter Profile Diary Question Number 5, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses

Assessed was the mean change from baseline in the percentage of "yes" responses to the Sexual Encounter Profile Diary question number 5: "Were you satisfied overall with this sexual experience?" Data are presented as the mean percentage of participants who answered "yes".

Time frame:
Baseline and 14 days double-blind period
Reported as:
Least squares mean · percentage of participants
Sexual Encounter Profile Diary Question Number 5, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses
percentage of participantsTadalafil 2.5 mgTadalafil 5 mgPlacebo
Sexual Encounter Profile Diary Question Number 5, Change From Baseline to Post Baseline During the Double-blind Period in Percentage of Yes Responses20.45 ± 2.8225.60 ± 2.846.52 ± 2.71
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 13.92 · 95% CI 6.30 to 21.55Included were terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction.
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = <0.001 (No adjustment for multiplicity.) · Mean difference (final values): 19.07 · 95% CI 11.40 to 26.75Included were terms for baseline value of the efficacy variable, treatment, site, and the baseline-by-treatment interaction.
SecondarySexual Encounter Profile Diary Question 3, the Overall Distribution of Time to Onset by Yes Responses

Assessed was the median time to onset of efficacy (day when 50% of participants have had at least 1 successful intercourse attempt) within the first 4 days of therapy based on a "yes" response to the sexual encounter profile diary question 3: "Did your erection last long enough for you to have successful intercourse?" Data are based on participants who responded "yes". For the placebo group, onset of efficacy was not reached within the first 4 days of therapy, therefore, the analysis timeframe was expanded for this group to determine the median time to onset of efficacy.

Time frame:
4 days double-blind period
Reported as:
Median · days
Sexual Encounter Profile Diary Question 3, the Overall Distribution of Time to Onset by Yes Responses
daysTadalafil 2.5 mgTadalafil 5 mgPlacebo
Sexual Encounter Profile Diary Question 3, the Overall Distribution of Time to Onset by Yes Responses4.0 ± 0.8783.0 ± 0.3846.0 ± 2.283
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · Log Rank · p = 0.301 (No adjustment for multiplicity.)
  • Tadalafil 5 mg vs Placebo · Log Rank · p = 0.046 (No adjustment for multiplicity.)
SecondarySexual Encounter Profile Diary Question 3, Daily Cumulative Percentage of Successful Intercourse Attempts

Assessed was the cumulative precentage of successful intercourse attempts (successful attempts relative to the total number of intercourse attempts) over the 14-day double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?" Data are presented as the proportion of intercourse attempts for which participants answered "yes" relative to the total number of intercourse attempts. Total number of attempts = TNA.

Time frame:
14 days during double-blind period
Reported as:
Number · percentage of total number of attempts
Sexual Encounter Profile Diary Question 3, Daily Cumulative Percentage of Successful Intercourse Attempts
percentage of total number of attemptsTadalafil 2.5 mgTadalafil 5 mgPlacebo
<=day14 (TNA: n=905; n=813; n=781)45.146.630.9
<=day13 (TNA: n=877; n=777; n=755)44.546.231.2
<=day12 (TNA: n=827; n=730; n=711)44.045.930.8
<=day11 (TNA: n=774; n=678; n=668)43.244.930.7
<=day10 (TNA: n=726; n=626; n=625)41.944.230.6
<=day9 (TNA: n=668; n=574; n=572)40.243.729.8
<=day8 (TNA: n=608; n=534; n=523)39.542.829.6
<=day7 (TNA: n=563; n=483; n=481)38.742.428.8
<=day6 (TNA: n=505; n=439; n=435)37.441.627.9
<=day5 (TNA: n=464; n=402; n=396)36.641.427.4
<=day4 (TNA: n=412; n=350; n=352)37.140.926.2
<=day3 (TNA: n=324; n=265; n=262)35.538.527.2
<=day2 (TNA: n=214; n=179; n=175)35.838.928.0
<=day1 (TNA: n=109; n=83; n=83)38.633.732.1
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=14. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=13. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=12. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=11. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=10. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=9. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = 0.002 (P-value for day \<=8. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = 0.001 (P-value for day \<=7. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = 0.002 (P-value for day \<=6. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = 0.002 (P-value for day \<=5. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = 0.002 (P-value for day \<=4. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = 0.009 (P-value for day \<=3. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 2.5 mg vs Placebo · Regression, Logistic · p = 0.038 (P-value for day \<=2. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=14. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=13. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=12. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=11. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=10. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=9. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=8. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=7. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=6. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=5. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value for day \<=4. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = 0.003 (P-value for day \<=3. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = 0.008 (P-value for day \<=2. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
  • Tadalafil 5 mg vs Placebo · Regression, Logistic · p = 0.246 (P-value for day \<=1. No adjustment for multiplicity.)Response = Treatment + Pooled Site + Severity of ED at Baseline.
SecondarySexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind and Open-label Periods for Participants Who Were Assigned to Placebo in the Double-blind Treatment Period

Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"

Time frame:
14 days double-blind and 14 days open-label
Reported as:
Mean · percentage successful attempts
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind and Open-label Periods for Participants Who Were Assigned to Placebo in the Double-blind Treatment Period
percentage successful attemptsPlacebo Double-blindTadalafil 5 mg Open-label
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind and Open-label Periods for Participants Who Were Assigned to Placebo in the Double-blind Treatment Period32.21 ± 35.3568.27 ± 38.76
Statistical analysis
  • Placebo Double-blind vs Tadalafil 5 mg Open-label · t-test, 2 sided · p = <0.001 · Mean difference (final values): -36.05the estimated mean difference shows changes in the double-blind treatment phase minus changes in the open label treatment phase
SecondarySexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 2.5 mg in the Double-blind Treatment Period

Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"

Time frame:
14-day double-blind and 14-day open-label
Reported as:
Mean · percentage successful attempts
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 2.5 mg in the Double-blind Treatment Period
percentage successful attemptsTadalafil 2.5 mg Double-blindTadalafil 5 mg Open-label
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 2.5 mg in the Double-blind Treatment Period46.11 ± 37.1768.33 ± 40.10
Statistical analysis
  • Tadalafil 2.5 mg Double-blind vs Tadalafil 5 mg Open-label · t-test, 2 sided · p = <0.001 · Mean difference (final values): -22.22the estimated mean difference shows changes in the double-blind treatment phase minus changes in the open label treatment phase
SecondarySexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 5 mg in the Double-blind Treatment Period

Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts over the 14-day open-label treatment period compared with the 14-day double-blind treatment period by dose group during the double-blind treatment period. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"

Time frame:
14-day double-blind and 14-day open-label
Reported as:
Mean · percentage successful attempts
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 5 mg in the Double-blind Treatment Period
percentage successful attemptsTadalafil 5 mg Double-blindTadalafil 5 mg Open-label
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses in the Double-blind Period and the Open-label Period for Participants Who Were Assigned to Tadalafil 5 mg in the Double-blind Treatment Period49.54 ± 38.6067.70 ± 38.98
Statistical analysis
  • Tadalafil 5 mg Double-blind vs Tadalafil 5 mg Open-label · t-test, 2 sided · p = <0.001 · Mean difference (final values): -18.16the estimated mean difference shows changes in the double-blind treatment phase minus changes in the open label treatment phase
SecondarySexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind Period and the Open-label Period for Participants Who Didn't Respond to Tadalafil 2.5 mg During Double-blind Period

Assessed were percentages of successful intercourse attempts relative to the total number of intercourse attempts in both treatment periods. A successful attempt was defined by a "yes" response to the sexual encounter profile diary question #3: "Did your erection last long enough for you to have successful intercourse?"

Time frame:
14 days double-blind and 14 days open-label
Reported as:
Mean · percentage successful attempts
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind Period and the Open-label Period for Participants Who Didn't Respond to Tadalafil 2.5 mg During Double-blind Period
percentage successful attemptsTadalafil 2.5 mg Double-blindTadalafil 5 mg Open-label
Sexual Encounter Profile Diary Question 3, Percentages of Yes Responses During the Double-blind Period and the Open-label Period for Participants Who Didn't Respond to Tadalafil 2.5 mg During Double-blind Period32.51 ± 40.7757.62 ± 45.27
Statistical analysis
  • Tadalafil 2.5 mg Double-blind vs Tadalafil 5 mg Open-label · t-test, 2 sided · p = <0.001 · Mean difference (final values): -25.11the estimated mean difference shows changes in the double-blind treatment phase minus changes in the open label treatment phase

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil 2.5 mg—0/121 (0%)13/121 (10.7%)
Tadalafil 5 mg—0/118 (0%)12/118 (10.2%)
Placebo—0/133 (0%)8/133 (6%)
Tadalafil 2.5 mg to Tadalafil 5 mg—0/111 (0%)6/111 (5.4%)
Tadalafil 5 mg to Tadalafil 5 mg—0/108 (0%)9/108 (8.3%)
Placebo to Tadalafil 5 mg—0/124 (0%)4/124 (3.2%)
Most frequent other events
Showing 10 of 39
Most frequent other events
EventTadalafil 2.5 mgTadalafil 5 mgPlaceboTadalafil 2.5 mg to Tadalafil 5 mgTadalafil 5 mg to Tadalafil 5 mgPlacebo to Tadalafil 5 mg
HeadacheNervous system disorders1/1211/1180/1333/1111/1081/124
Back painMusculoskeletal and connective tissue disorders1/1213/1180/1330/1110/1081/124
Sinus congestionRespiratory, thoracic and mediastinal disorders0/1210/1180/1330/1112/1080/124
MyalgiaMusculoskeletal and connective tissue disorders0/1212/1181/1330/1110/1081/124
Upper respiratory tract infectionInfections and infestations2/1210/1180/1331/1110/1080/124
Muscle spasmsMusculoskeletal and connective tissue disorders0/1210/1182/1330/1110/1080/124
DyspepsiaGastrointestinal disorders1/1211/1181/1330/1111/1080/124
Gastrointestinal disorderGastrointestinal disorders0/1210/1180/1330/1111/1080/124
CellulitisInfections and infestations0/1210/1180/1330/1111/1080/124
Localised infectionInfections and infestations0/1210/1180/1330/1111/1080/124

Baseline characteristics

Age Continuous
Age Continuous(years)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Mean59.63 ± 10.0257.68 ± 11.0759.23 ± 10.6358.87 ± 10.58
Sex: Female, Male
Sex: Female, Male(Participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Female0000
Male121118133372
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
American Indian or Alaska Native4004
Asian2417
Black or African American25212268
Multiple1629
Native Hawaiian or Other Pacific Islander0011
White8987107283
Region of Enrollment
Region of Enrollment(participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
United States121118133372
Sexual Encounter Profile Diary question number 1
Sexual Encounter Profile Diary question number 1(percentage of participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Mean74.04 ± 35.6475.22 ± 35.6982.26 ± 28.9877.34 ± 33.55
Sexual Encounter Profile Diary question number 2
Sexual Encounter Profile Diary question number 2(percentage of participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Mean52.70 ± 40.5854.20 ± 39.4756.16 ± 37.1454.41 ± 38.94
Sexual Encounter Profile Diary question number 3
Sexual Encounter Profile Diary question number 3(percentage of participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Mean30.90 ± 36.9925.42 ± 32.6229.95 ± 34.8528.80 ± 34.85
Sexual Encounter Profile Diary question number 4
Sexual Encounter Profile Diary question number 4(percentage of participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Mean8.33 ± 19.184.96 ± 13.198.36 ± 16.887.26 ± 16.64

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46285, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2009
First posted
Feb 2, 2009
Start
Feb 2009
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Aug 18, 2010
Last update
Aug 24, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00833638
First posted
Feb 2, 2009
Start date
Feb 2009
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Aug 18, 2010
Last update
Aug 24, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion